SCHEDULE: FMR LLC & Abigail Johnson Disclose 6.7% Stake in CAMP4

FMR LLC and Abigail P. Johnson have disclosed a 6.7% beneficial ownership stake in CAMP4 Therapeutics Corporation, held in the ordinary course of business.

Summary

• FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing their beneficial ownership in CAMP4 Therapeutics Corporation.
• As of October 31, 2025, FMR LLC and Abigail P. Johnson beneficially own 3,145,663 shares of CAMP4 Therapeutics Corporation's common stock.
• This aggregate amount represents 6.7% of the total outstanding common stock of CAMP4 Therapeutics Corporation.
• FMR LLC holds sole voting power over 3,144,334 shares and sole dispositive power over 3,145,663 shares.
• Abigail P. Johnson, as an individual and through her role at FMR LLC, is deemed to beneficially own the same 3,145,663 shares with sole dispositive power.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of CAMP4 Therapeutics Corporation.
• The filing identifies Fidelity Management & Research Company LLC (Investment Adviser) and Fidelity Management Trust Company (Bank) as entities within the FMR group that beneficially own shares.
• No single other person's interest in the common stock exceeds five percent of the total outstanding common stock.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable institutional investor like FMR LLC is generally viewed positively as it indicates confidence in the company's long-term prospects without suggesting immediate activist intervention.

Positives

• A significant institutional investor, FMR LLC, and its CEO, Abigail P. Johnson, have disclosed a substantial 6.7% stake, indicating confidence in CAMP4 Therapeutics Corporation.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding CAMP4 Therapeutics Corporation's future performance or strategic direction, as it is solely an ownership disclosure.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

The disclosure of a significant stake by a major asset manager like FMR LLC in a biotechnology company like CAMP4 Therapeutics Corporation can signal institutional interest in the life sciences sector, particularly in companies with potential for innovation or growth. Such investments are common as large funds diversify their portfolios across various industries.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by FMR LLC and Abigail P. Johnson may be viewed positively, potentially increasing investor confidence and attracting further institutional interest.
• Management: The statement that the investment is not for the purpose of changing or influencing control suggests that current management can continue executing its strategy without immediate pressure from this particular shareholder.

Key Dates

Recommendation

The filing indicates a significant, passive institutional investment by FMR LLC and Abigail P. Johnson, representing 6.7% of CAMP4 Therapeutics Corporation's common stock. This suggests a vote of confidence from a major asset manager, which is generally a positive signal. However, as a Schedule 13G, it does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. The investment is stated to be in the ordinary course of business and not for control, implying a long-term, non-activist position. Therefore, for existing investors, holding the stock is a reasonable approach given the institutional backing, while new investors would need to conduct further due diligence on CAMP4's fundamentals beyond this ownership disclosure.

Keywords

CAMP4 Therapeutics Corporation, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, Investment Disclosure